PR-104

PR-104
Identifiers
	IUPAC name [2-({2-[(2-Bromoethyl)[2-(methanesulfonyloxy)ethyl]amino]-3,5-dinitrophenyl}formamido)ethoxy]phosphonic acid;
CAS Number	851627-62-8 ;
PubChem CID	11455973;
ChemSpider	9630821;
UNII	V16D2ZT7DT;
Chemical and physical data
Formula	C14H20BrN4O12PS
Molar mass	579.27 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CS(=O)(=O)OCCN(CCBr)c1c(cc(cc1[N+](=O)[O-])[N+](=O)[O-])C(=O)NCCOP(=O)(O)O;
	InChI InChI=1S/C14H20BrN4O12PS/c1-33(28,29)31-7-5-17(4-2-15)13-11(14(20)16-3-6-30-32(25,26)27)8-10(18(21)22)9-12(13)19(23)24/h8-9H,2-7H2,1H3,(H,16,20)(H2,25,26,27); Key:GZSOKPMDWVRVMG-UHFFFAOYSA-N;

Short description: Chemical compound

PR-104 is a drug from the class of hypoxia-activated prodrugs (HAPs),^[1] which is being researched as a potential anti-cancer therapeutic agent. It is a phosphate ester “pre-prodrug” that is rapidly converted to the HAP PR-104A in the body. PR-104A is in turn metabolised to reactive nitrogen mustard DNA crosslinking agents in hypoxic tissues such as found in solid tumours.^[2]^[3]^[4] Following initial clinical studies,^[5]^[6] it was discovered that PR-104A is also activated by the enzyme AKR1C3, independently of hypoxia.^[7] Hypoxia in the bone marrow of patients with leukaemia,^[8]^[9] and high activity of AKR1C3 in some leukaemia subtypes ^[10]^[11]^[12] has led to interest in clinical trials of PR-104 in relapsed refractory acute leukaemias.^[13]^[14]

References

↑ "Targeting hypoxia in cancer therapy". Nature Reviews. Cancer 11 (6): 393–410. June 2011. doi:10.1038/nrc3064. PMID 21606941.
↑ "Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104". Clinical Cancer Research 13 (13): 3922–32. July 2007. doi:10.1158/1078-0432.CCR-07-0478. PMID 17606726. http://clincancerres.aacrjournals.org/content/13/13/3922.long.
↑ "DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity". Cancer Research 69 (9): 3884–91. May 2009. doi:10.1158/0008-5472.CAN-08-4023. PMID 19366798. http://cancerres.aacrjournals.org/content/69/9/3884.long.
↑ "Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling". Frontiers in Oncology 3: 314. December 2013. doi:10.3389/fonc.2013.00314. PMID 24409417.
↑ "A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors". Cancer Chemotherapy and Pharmacology 65 (4): 791–801. March 2010. doi:10.1007/s00280-009-1188-1. PMID 20012293.
↑ "A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients". BMC Cancer 11 (1): 432. October 2011. doi:10.1186/1471-2407-11-432. PMID 21982454.
↑ "The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3". Cancer Research 70 (4): 1573–84. February 2010. doi:10.1158/0008-5472.CAN-09-3237. PMID 20145130. http://cancerres.aacrjournals.org/content/70/4/1573.long.
↑ "Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104". PLOS ONE 6 (8): e23108. 11 August 2011. doi:10.1371/journal.pone.0023108. PMID 21853076. Bibcode: 2011PLoSO...623108B.
↑ "Targeting hypoxia in the leukemia microenvironment". International Journal of Hematologic Oncology 2 (4): 279–288. August 2013. doi:10.2217/ijh.13.32. PMID 24490034.
↑ "A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells". Biochemical Pharmacology 88 (1): 36–45. March 2014. doi:10.1016/j.bcp.2013.12.019. PMID 24434189.
↑ "AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia". Blood 126 (10): 1193–202. September 2015. doi:10.1182/blood-2014-12-618900. PMID 26116659.
↑ "Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3". Pharmaceuticals 14 (12): 1231. November 2021. doi:10.3390/ph14121231. PMID 34959631.
↑ "Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia". Haematologica 100 (7): 927–34. July 2015. doi:10.3324/haematol.2014.118455. PMID 25682597.
↑ "Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs". Cancer Chemotherapy and Pharmacology 77 (3): 441–57. March 2016. doi:10.1007/s00280-015-2920-7. PMID 26811177.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/PR-104. Read more

[1] "Targeting hypoxia in cancer therapy". Nature Reviews. Cancer 11 (6): 393–410. June 2011. doi:10.1038/nrc3064. PMID 21606941.

[2] "Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104". Clinical Cancer Research 13 (13): 3922–32. July 2007. doi:10.1158/1078-0432.CCR-07-0478. PMID 17606726. http://clincancerres.aacrjournals.org/content/13/13/3922.long.

[3] "DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity". Cancer Research 69 (9): 3884–91. May 2009. doi:10.1158/0008-5472.CAN-08-4023. PMID 19366798. http://cancerres.aacrjournals.org/content/69/9/3884.long.

[pmid24409417-4] "Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling". Frontiers in Oncology 3: 314. December 2013. doi:10.3389/fonc.2013.00314. PMID 24409417.

[5] "A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors". Cancer Chemotherapy and Pharmacology 65 (4): 791–801. March 2010. doi:10.1007/s00280-009-1188-1. PMID 20012293.

[6] "A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients". BMC Cancer 11 (1): 432. October 2011. doi:10.1186/1471-2407-11-432. PMID 21982454.

[7] "The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3". Cancer Research 70 (4): 1573–84. February 2010. doi:10.1158/0008-5472.CAN-09-3237. PMID 20145130. http://cancerres.aacrjournals.org/content/70/4/1573.long.

[8] "Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104". PLOS ONE 6 (8): e23108. 11 August 2011. doi:10.1371/journal.pone.0023108. PMID 21853076. Bibcode: 2011PLoSO...623108B.

[9] "Targeting hypoxia in the leukemia microenvironment". International Journal of Hematologic Oncology 2 (4): 279–288. August 2013. doi:10.2217/ijh.13.32. PMID 24490034.

[10] "A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells". Biochemical Pharmacology 88 (1): 36–45. March 2014. doi:10.1016/j.bcp.2013.12.019. PMID 24434189.

[11] "AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia". Blood 126 (10): 1193–202. September 2015. doi:10.1182/blood-2014-12-618900. PMID 26116659.

[pmid34959631-12] "Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3". Pharmaceuticals 14 (12): 1231. November 2021. doi:10.3390/ph14121231. PMID 34959631.

[13] "Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia". Haematologica 100 (7): 927–34. July 2015. doi:10.3324/haematol.2014.118455. PMID 25682597.

[pmid26811177-14] "Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs". Cancer Chemotherapy and Pharmacology 77 (3): 441–57. March 2016. doi:10.1007/s00280-015-2920-7. PMID 26811177.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

Identifiers

IUPAC name [2-({2-[(2-Bromoethyl)[2-(methanesulfonyloxy)ethyl]amino]-3,5-dinitrophenyl}formamido)ethoxy]phosphonic acid
CAS Number	851627-62-8^Y
PubChem CID	11455973
ChemSpider	9630821
UNII	V16D2ZT7DT
Chemical and physical data
Formula	C₁₄H₂₀BrN₄O₁₂PS
Molar mass	579.27 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CS(=O)(=O)OCCN(CCBr)c1c(cc(cc1[N+](=O)[O-])[N+](=O)[O-])C(=O)NCCOP(=O)(O)O
InChI InChI=1S/C14H20BrN4O12PS/c1-33(28,29)31-7-5-17(4-2-15)13-11(14(20)16-3-6-30-32(25,26)27)8-10(18(21)22)9-12(13)19(23)24/h8-9H,2-7H2,1H3,(H,16,20)(H2,25,26,27) Key:GZSOKPMDWVRVMG-UHFFFAOYSA-N

PR-104

Topic: Chemistry

References